• 1. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 2. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 3. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 4. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 5. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555

Recent Advances in the Application of (3-Ethylpyrrolidin-3-yl)methanol (CAS: 1001754-43-3) in Chemical Biology and Pharmaceutical Research

The compound (3-Ethylpyrrolidin-3-yl)methanol (CAS: 1001754-43-3) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its versatile applications as a key intermediate in the synthesis of bioactive molecules. This research brief aims to summarize the latest findings regarding its synthesis, pharmacological properties, and potential therapeutic applications, based on recent peer-reviewed publications and patent filings.

Recent studies have highlighted the role of (3-Ethylpyrrolidin-3-yl)methanol in the development of novel central nervous system (CNS) therapeutics. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its utility as a precursor for the synthesis of sigma-1 receptor ligands, which show promise in treating neurodegenerative diseases such as Alzheimer's and Parkinson's. The compound's unique pyrrolidine scaffold enables efficient modification to enhance blood-brain barrier permeability, a critical factor in CNS drug development.

In synthetic chemistry, advancements have been made in the enantioselective synthesis of (3-Ethylpyrrolidin-3-yl)methanol derivatives. A recent Nature Communications paper (2024) described a novel asymmetric hydrogenation protocol using chiral iridium catalysts, achieving >99% enantiomeric excess. This methodological breakthrough addresses previous challenges in obtaining optically pure forms of the compound, which is crucial for pharmaceutical applications where stereochemistry significantly impacts biological activity.

Pharmacokinetic studies of (3-Ethylpyrrolidin-3-yl)methanol-based compounds have revealed favorable metabolic stability profiles. Research published in Drug Metabolism and Disposition (2023) demonstrated that derivatives exhibit prolonged half-lives in preclinical models, with minimal cytochrome P450 inhibition. These properties make the scaffold particularly attractive for developing long-acting medications with reduced drug-drug interaction potential.

Emerging applications in antimicrobial drug discovery have also been reported. A 2024 study in ACS Infectious Diseases identified (3-Ethylpyrrolidin-3-yl)methanol derivatives with potent activity against multidrug-resistant Gram-positive pathogens, including MRSA. The mechanism appears to involve disruption of bacterial membrane integrity, representing a novel approach to addressing antibiotic resistance.

Several pharmaceutical companies have recently filed patents covering novel applications of (3-Ethylpyrrolidin-3-yl)methanol derivatives. A notable example includes WO2023187567, which claims compositions for treating chronic pain through modulation of TRPV1 receptors. These developments suggest growing commercial interest in the scaffold's therapeutic potential.

Future research directions are likely to focus on expanding the structural diversity of (3-Ethylpyrrolidin-3-yl)methanol derivatives and exploring their applications in targeted drug delivery systems. The compound's chemical versatility and demonstrated biological activities position it as a valuable building block for next-generation pharmaceuticals across multiple therapeutic areas.

• 1369498-02-1(2-Azaspiro[4.6]undecan-4-ylmethanol)
• 1515457-62-1(3-(propan-2-yl)pyrrolidin-3-ylmethanol)
• 1212106-97-2(((3aR,7aR)-octahydro-1H-isoindol-3a-yl)methanol HCl)
• 77415-63-5(2-3-(hydroxymethyl)pyrrolidin-3-ylethan-1-ol)
• 116339-10-7(3-Pyrrolidinemethanol, 1-octadecyl-)
• 1803588-80-8((3-propylpyrrolidin-3-yl)methanol hydrochloride)
• 444193-03-7((3aS,6aS)-hexahydro-Cyclopenta[c]pyrrole-3a(1H)-methanol)
• 848616-41-1((3aS,7aR)-7a-(hydroxymethyl)-octahydro-1H-isoindol-3a-ylmethanol)
• 848616-44-4(5-azaspiro[2.4]heptan-7-ylmethanol)
• 444193-01-5([(3aR,6aR)-octahydrocyclopenta[c]pyrrol-3a-yl]methanol)